CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 526 enrolled
Drug / intervention
PRO-SERO-COVother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04426006
NCT04426006N/ACompleted

Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic - PRO-SERO-COV

Institut Bergonié·interventional·Posted Jun 11, 2020·Updated Sep 3, 2025

In Brief

A clinical study evaluating PRO-SERO-COV for Sars-CoV2 and Serum; Disease. Completed, enrolled 526 participants across 1 site.

Detailed Summary

The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue. Knowing the evolution of this response over time in this population can help answer outstanding questions. The PRO-SERO-COV study is a seroprevalence study of caregivers working in the hospital sector with a follow-up at 3 months and 12 months. The objective is to evaluate and monitor at 3 and 12 months the serological immune status to an infection by the SARS-CoV-2 virus in active volunteer professionals working at the Institut Bergonié with different types of exposure: healthcare professionals and professionals in other services.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 11, 2020
Enrollment StartJun 18, 2020
Primary CompletionJan 26, 2021
Study CompletionOct 4, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.1 years ago

Interventions

PRO-SERO-COVother

At inclusion, 3 months and 12 months : * blood sample (2 x 5ml) * self-administered questionnaire